drugset / Trial / NCT07211438
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
Phase 2
Not yet recruiting
40 enrolled
Centre for Addiction and Mental Health
University Health Network, Toronto · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to determine the role of psilocybin monitors on the effects of psilocybin therapy in adults with treatment resistant depression.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2028-04-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 25 mg | — |
Indications
No indication recorded.